Abstract
Some deaf men who use American Sign Language (ASL) experience barriers in patient-physician communication which may leave them at disparity for shared decision making compared to hearing men. Transparent communication accessibility is needed between deaf male ASL users and their physicians to maximize the benefit to risk ratio of using the prostate-specific antigen (PSA) as a screening tool for early detection. The objective is to compare shared decision-making outcomes between deaf and hearing males who are (1) age-eligible for PSA screening and (2) younger than 45 years old with a family history of cancer. An accessible health survey including questions about PSA test, PCC, modes of communication, and cancer history was administered in ASL to a nationwide sample of deaf adults from February 2017 to April 2018. Two subsamples were created: (1) 45- to 69-year-old men who were age-eligible for PSA testing and (2) 18- to 44-year-old men with a family history of cancer. Age-eligible and younger deaf men with a family history of cancer are at disparity for shared decision making compared to their hearing peers. Regardless of age and PSA testing status, deaf men felt significantly less engaged in shared decision making with their health care providers compared to hearing men. Participation in shared decision making requires not only accessible communication but also cultural competency in working with deaf patients. This is critical in the shared decision-making era in maximizing the benefit of prostate cancer screening in deaf male patient population.
Similar content being viewed by others
References
US Preventive Services Task Force (2018) Screening for prostate cancer US preventive services task force recommendation statement. JAMA 319(18):1901–1913. https://doi.org/10.1001/jama.2018.3710
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC, for the PLCO Project Team (2012) Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104:125–132. https://doi.org/10.1093/jnci/djr500
Alpert PF (2018) New evidence for the benefit of prostate-specific antigen screening: data from 400,887 Kaiser Permanente patients. Urology 118:119–126. https://doi.org/10.1016/j.urology.2018.02.049
Moyer VA (2012) Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. https://doi.org/10.7326/0003-4819-157-2-201207170-00459
Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW Cancer Screening in the United States, 2010: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010. https://doi.org/10.3322/caac.20063.Available
Gulati R, Gore JL, Etzioni R (2013) Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 158:145–153. https://doi.org/10.7326/0003-4819-158-3-201302050-00003
Drazer MW, Huo D, Eggener SE (2015) National prostate cancer screening rates after the 2012 US preventive services task force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 33:2416–2423. https://doi.org/10.1200/JCO.2015.61.6532
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ et al (2016) NCCN guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw. https://doi.org/10.6004/JNCCN.2016.0060
Durand M-A, Carpenter L, Dolan H, Bravo P, Mann M, Bunn F, Elwyn G (2014) Do interventions designed to support shared decision-making reduce health inequalities? A systematic review and meta-analysis. PLoS One 9:e94670. https://doi.org/10.1371/journal.pone.0094670
Orsi JM, Margellos-Anast H, Perlman TS, Giloth BE, Whitman S (2007) Cancer screening knowledge, attitudes, and behaviors among culturally deaf adults: implications for informed decision making. Cancer Detect Prev 31:474–479. https://doi.org/10.1016/j.cdp.2007.10.008
McKee MM, Barnett SL, Block RC, Pearson TA (2011) Impact of communication on preventive services among deaf American sign language users. Am J Prev Med 41:75–79. https://doi.org/10.1016/j.amepre.2011.03.004
McKee MM, Paasche-Orlow MK, Winters PC, Fiscella K, Zazove P, Sen A et al (2015) Assessing health literacy in deaf American sign language users. J Health Commun 20(Suppl 2):92–100. https://doi.org/10.1080/10810730.2015.1066468
Steinberg AG, Barnett S, Meador HE, Wiggins EA, Zazove P (2006) Health care system accessibility: experiences and perceptions of deaf people. J Gen Intern Med 21:260–266. https://doi.org/10.1111/j.1525-1497.2006.00340.x
Kaskowitz Iii SR, Nakaji MC, Clark KL, Gunsauls DC, Sadler GR (2006) Bringing prostate cancer education to deaf men. Cancer Detect Prev 30:439–448. https://doi.org/10.1016/j.cdp.2006.09.001
Sacks L, Nakaji M, Harry KM, Oen M, Malcarne VL, Sadler GR (2013) Testicular cancer knowledge among deaf and hearing men. J Cancer Educ 28:503–508. https://doi.org/10.1007/s13187-013-0493-x
Folkins A, Sadler GR, Ko C, Branz P, Marsh S, Bovee M (2005) Improving the deaf community’s access to prostate and testicular cancer information: a survey study. BMC Public Health 5. https://doi.org/10.1186/1471-2458-5-63
Han PKJ, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, Klabunde CN (2013) National evidence on the use of shared decision making in prostate-specific antigen screening. Ann Fam Med 11:306–314. https://doi.org/10.1370/afm.1539
Kushalnagar P, Harris R, Paludneviciene R, Hoglind T (2017) Health Information National Trends Survey in American Sign Language (HINTS-ASL): protocol for the cultural adaptation and linguistic validation of a national survey. JMIR Res Protoc. https://doi.org/10.2196/resprot.8067
Dunn AS, Shridharani KV, Lou W, Bernstein J, Horowitz CR (2001) Physician-patient discussions of controversial cancer screening tests. Am J Prev Med 20:130–134. https://doi.org/10.1016/S0749-3797(00)00288-9
Haskard Zolnierek KB, DiMatteo MR (2009) Physician communication and patient adherence to treatment. Med Care 47:826–834. https://doi.org/10.1097/MLR.0b013e31819a5acc
Robinson JH, Callister LC, Berry JA, Dearing KA (2008) Patient-centered care and adherence: definitions and applications to improve outcomes. J Am Acad Nurse Pract 20:600–607. https://doi.org/10.1111/j.1745-7599.2008.00360.x
O’Hearn A (2006) Deaf women’s experiences and satisfaction with prenatal care: a comparative study. Fam Med 38:712–716
Woods-Burnham L, Stiel L, Wilson C, Montgomery S, Durán AM, Ruckle HR, Thompson RA, de León M, Casiano CA (2018) Physician consultations, prostate cancer knowledge, and PSA screening of African American men in the era of shared decision-making. Am J Mens Health 12:751–759. https://doi.org/10.1177/1557988318763673
Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study. J Natl Cancer Inst 2016;108:djw110. doi:https://doi.org/10.1093/jnci/djw110
Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O (2018) Concordance of non-low-risk disease among pairs of brothers with prostate Cancer. J Clin Oncol 36:1847–1852. https://doi.org/10.1200/JCO.2017.76.6907
Albright F, Stephenson RA, Agarwal N, Teerlink CC, Lowrance WT, Farnham JM, Albright LAC (2015) Prostate cancer risk prediction based on complete prostate cancer family history. Prostate 75:390–398. https://doi.org/10.1002/pros.22925
Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, Govindasami K, Guy M, Ellis S, Frost D, Bancroft E, Cole T, Tischkowitz M, Kennedy MJ, Eason J, Brewer C, Evans DG, Davidson R, Eccles D, Porteous ME, Douglas F, Adlard J, Donaldson A, Antoniou AC, Kote-Jarai Z, Easton DF, Olmos D, Eeles R (2015) Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 68:186–193. https://doi.org/10.1016/j.eururo.2014.10.022
Funding
This work was approved by Gallaudet’s Institutional Review Board and supported by the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health (7R15DC014816–02 awarded to Poorna Kushalnagar, Ph.D.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of Interest
The authors declare that they have no conflict of interest.
Financial Disclosure
No competing financial interests exist.
Rights and permissions
About this article
Cite this article
Kushalnagar, P., Hill, C., Carrizales, S. et al. Prostate-Specimen Antigen (PSA) Screening and Shared Decision Making Among Deaf and Hearing Male Patients. J Canc Educ 35, 28–35 (2020). https://doi.org/10.1007/s13187-018-1436-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13187-018-1436-3